Changeflow GovPing Healthcare & Life Sciences Small Molecule Protein Synthesis Modulators
Routine Notice Added Final

Small Molecule Protein Synthesis Modulators

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO published patent application US20260109696A1 assigned to Interdict Bio, Inc., filed September 19, 2025 (Application No. 19333657), covering small molecule compounds and pharmaceutical compositions useful for modulating protein synthesis. The disclosed compounds and methods are directed to treating diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, and KRAS-G12D targets.

“The present disclosure provides compounds, and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification C07D covers heterocyclic organic compounds: the chemical core of most small-molecule drugs, including kinase inhibitors, GLP-1 receptor agonists, antibiotics, antivirals, and CNS therapies. Every newly published application in C07D lands in this feed, around 160 a month. Applications publish 18 months after filing, so this feed reveals what medicinal chemistry groups at Pfizer, Novartis, Roche, Shionogi, and others were synthesizing in the prior year and a half. Watch this if you run a medicinal chemistry program, file patent clearance for new drug candidates, scout competitor pipelines before clinical readouts, or track heterocyclic innovation across therapeutic areas.

What changed

The USPTO published patent application US20260109696A1 for small molecule protein synthesis modulators, filed by Interdict Bio, Inc. on September 19, 2025. The application discloses compounds and pharmaceutical compositions useful for modulating protein synthesis, along with methods of treating diseases or disorders associated with specified molecular targets including BCL-2, MYC, CCND1, MCL-1, ALK, and KRAS-G12D.

Pharmaceutical companies and researchers working in oncology and targeted protein degradation may need to assess whether their own compound portfolios or research programs overlap with the claimed subject matter, particularly for therapies addressing the specified cancer-related molecular targets.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS

Application US20260109696A1 Kind: A1 Apr 23, 2026

Assignee

Interdict Bio, Inc.

Inventors

Sogole Sami Bahmanyar, Lawrence Hamann, Zef Konst, David Gygi, Margot Meyers

Abstract

The present disclosure provides compounds, and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

CPC Classifications

C07D 417/14 A61K 31/40 A61K 31/4025 A61K 31/404 A61K 31/4155 A61K 31/416 A61K 31/4192 A61K 31/4196 A61K 31/422 A61K 31/427 A61K 31/4439 A61K 31/501 A61K 31/517 C07D 207/12 C07D 401/10 C07D 401/14 C07D 403/10 C07D 403/12 C07D 405/14 C07D 413/10 C07D 413/14 C07D 417/10 C07D 495/04 C07D 513/04

Filing Date

2025-09-19

Application No.

19333657

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Drug compound discovery
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!